EUVIMEDEUVIMED entdecken
Open Access

Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in sickle cell disease

Erica B Esrick, Leslie Lehmann, Amy Federico, Helene Vincon iD, Boya Liu, Heather Daley, Colleen Dansereau, Satiro N DeOliveira, John Everett, Pei-Chi Kao, Theodore B Moore, Emily Morris und 15 weitere

Blood · 2026

DOI: 10.1182/blood.2026033871 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2026. Verfasst von Erica B Esrick und 26 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Carrier Proteins, Gene Silencing, Genetic Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sickle cell disease (SCD) is characterized by chronic hemolysis, and painful vaso-occlusive episodes (VOE). High levels of fetal hemoglobin (HbF) attenuate the disease phenotype. We used a lentivirus vector (LVV) expressing a short hairpin RNA embedded in a microRNA (shmiR) that targets BCL11A in erythrocytes to induce HbF in a first-in-human study in SCD. The purpose of the study was to assess hematopoietic stem/progenitor cells collection, transduction parameters, safety, HbF induction, and durability. Eleven eligible patients with SCD underwent hematopoietic stem cell (HSC) collection. Plerixafor-mobilized peripheral blood HSCs required for manufacturing were obtained in 1 mobilization cycle for 10 of 11 participants, and 11 of 11 patient products were successfully manufactured with a median time to release of product of 39 days. Ten patients were infused with HSCs transduced with the shmiR vector. Engraftment occurred in all 10 patients. At a median follow-up of 58 months (range, 35-82) after infusion, there were no adverse events attributed to the vector. The transduction efficiency was 93.1%. One patient demonstrated low engraftment of the transduced cells and had suboptimal HbF induction. In the remaining 9 patients, at 2 years after treatment, the peripheral blood demonstrated 71% F cells with 11.9 pg HbF per F cells, and both parameters remained stable in 9 patients with ≥48 months follow-up. All patients who had VOEs before gene therapy demonstrated sustained mitigation of pain events. These data demonstrate excellent manufacturing efficiency, efficacy and safety of targeting BCL11A using a shmiR LVV, and long-term durability of the shmiR vector, leading to a pivotal, multisite, phase 2 trial that is currently underway (NCT05353647). This trial was registered at www.clinicaltrials.gov as NCT03282656.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellCarrier ProteinsGene SilencingGenetic TherapyGenetic VectorsMicroRNAsNuclear ProteinsRNA, Small InterferingAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultFetal HemoglobinHematopoietic Stem Cell TransplantationHematopoietic Stem CellsLentivirusRepressor ProteinsTransduction, Genetic

Substanzen

BCL11A protein, humanCarrier ProteinsFetal HemoglobinMicroRNAsNuclear ProteinsRepressor ProteinsRNA, Small Interfering

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA.
  • Division of Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Department of Pediatrics, Harvard Medical School, Boston, MA.
  • Gene Therapy Program, Boston Children's Hospital, Boston, MA.
  • Therapeutic Innovation Laboratory, Boston Children's Hospital, Boston, MA.
  • Connell and O'Reilly Families Cell Manipulation Core Facility, Dana-Farber Cancer Institute, Boston, MA.

ORCID-Profile: Helene Vincon, Helene Negre, Gavin D Roach, Jerome Ritz, P Ellen Grant, Donald B Kohn, Akshat Jain, Wendy B London, David G Justus

Zitieren

APA

Esrick, E. B., Lehmann, L., Federico, A., Vincon, H., Liu, B., Daley, H., Dansereau, C., DeOliveira, S. N., Everett, J., Kao, P. C., Moore, T. B., Morris, E., Negre, H., Shaw, K. L., Roach, G. D., Ritz, J., Roche, A. M., Silva, O., Grant, P. E., …, & Williams, D. A. (2026). Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in sickle cell disease. Blood. https://doi.org/10.1182/blood.2026033871

Vancouver

Esrick EB, Lehmann L, Federico A, Vincon H, Liu B, Daley H, et al. Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in sickle cell disease. Blood. 2026. doi:10.1182/blood.2026033871

BibTeX
@article{Esrick2026,
  author = {Esrick, Erica B and Lehmann, Leslie and Federico, Amy and Vincon, Helene and Liu, Boya and Daley, Heather and Dansereau, Colleen and DeOliveira, Satiro N and Everett, John and Kao, Pei-Chi and Moore, Theodore B and Morris, Emily and Negre, Helene and Shaw, Kit L and Roach, Gavin D and Ritz, Jerome and Roche, Aoife M and Silva, Olivia and Grant, P Ellen and Bushman, Frederic D and Kohn, Donald B and Jain, Akshat and London, Wendy B and Justus, David G and Armant, Myriam and Manis, John and Williams, David A},
  title = {Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in sickle cell disease},
  journal = {Blood},
  year = {2026},
  doi = {10.1182/blood.2026033871}
}
Kostenlos starten →